EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the unfolded protein response in cancer: mechanisms, small-molecule inhibitors, and translational challenges

Meizhen Lin, Zhijie Li

Frontiers in Immunology · 30.07.2026 · 17

DOI: 10.3389/fimmu.2026.1878552 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 30.07.2026. Verfasst von Meizhen Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Unfolded Protein Response, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endoplasmic reticulum (ER) stress, triggered by the accumulation of misfolded proteins, activates the unfolded protein response (UPR) to restore protein homeostasis. Dysregulated ER stress responses have emerged as critical modulators of cancer progression and immune escape, influencing the initiation, development and maintenance of antitumor immunity. The UPR is mediated by three principal sensors—PERK, IRE1α, and ATF6—each operating at distinct regulatory levels to coordinate translational reprogramming, RNA processing, and transcriptional reprogramming. Through these mechanisms, ER stress promotes malignant progression, tumor growth, and metastasis, while excessive activation can instead trigger cell death. Given this context-dependent duality, pharmacological targeting of the UPR has emerged as a promising anticancer strategy. For instance, IRE1α inhibitors block XBP1 splicing and RIDD-mediated immune escape, PERK inhibitors and ISR modulators reverse chemoresistance, ATF6-targeted strategies modulate ATF6-dependent tumor growth and treatment responses, and chemical chaperones exhibit both cytoprotective and antitumor effects depending on tumor context. This review integrates recent mechanistic insights into UPR-driven tumor progression, including pathway crosstalk, immune regulation, and immunotherapy resistance, with advances in small-molecule inhibitors, while critically evaluating their therapeutic potential and translational challenges in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Unfolded Protein ResponseNeoplasmsAntineoplastic AgentsHumansAnimalsEndoplasmic Reticulum StresseIF-2 KinaseProtein Serine-Threonine KinasesMolecular Targeted TherapySignal TransductionActivating Transcription Factor 6Endoribonucleases

Stichwörter der Autor:innen

ATF6IRE1αPERKcancer therapychemical chaperonesunfolded protein response

Substanzen

Antineoplastic AgentseIF-2 KinaseProtein Serine-Threonine KinasesActivating Transcription Factor 6Endoribonucleases

Autor:innen und Institutionen

  • Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
  • Liaoning Key Laboratory of Research and Application of Animal Models for Environmental and Metabolic Diseases, Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, China.

Zitieren

APA

Lin, M., & Li, Z. (2026). Targeting the unfolded protein response in cancer: mechanisms, small-molecule inhibitors, and translational challenges. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1878552

Vancouver

Lin M, Li Z. Targeting the unfolded protein response in cancer: mechanisms, small-molecule inhibitors, and translational challenges. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1878552

BibTeX
@article{Lin2026,
  author = {Lin, Meizhen and Li, Zhijie},
  title = {Targeting the unfolded protein response in cancer: mechanisms, small-molecule inhibitors, and translational challenges},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1878552}
}
Kostenlos starten →